RedHill s Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue | ANP Pers Support perssupport.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perssupport.nl Daily Mail and Mail on Sunday newspapers.
Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study
Remestemcel-L was being studied in patients with COVID-19-related acute respiratory distress
Australian biotech company Mesoblast announced on Friday that its stem cell therapy remestemcel-L failed to meet the primary endpoint in a phase 3 COVID-19 trial.
Remestemcel-L was being studied in ventilator-dependent COVID-19 patients with moderate-to-severe acute respiratory distress (ARDS).
According to Mesoblast, the trial was aiming to achieve a primary endpoint of 43% reduction in mortality at 30 days for treatment with remestemcel-L, in addition to maximal care.
However, following a third interim analysis of the first 180 patients, the trial’s Data Safety Monitoring Board (DSMB) reported that it is not likely the treatment will achieve that specified endpoint.
News Category Global Banking & Finance Reviews
Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Company concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Modernas vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.
FDA Grants Emergency Use Authorization to Moderna COVID-19 Vaccine pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
Total of 200 million doses ordered by the
U.S government to date;
Approximately 20 million doses will be delivered by the end of
December 2020
U.S. licensure in 2021
CAMBRIDGE, Mass. (BUSINESS WIRE) Dec. 18, 2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the
U.S. Food and Drug Administration’s (FDA) has authorized the emergency use of mRNA-1273, Moderna’s vaccine against COVID-19 in individuals 18 years of age or older. The Moderna COVID-19 Vaccine is now authorized for distribution and use under an Emergency Use Authorization (EUA). Delivery to the
U.S. Government will begin immediately.